Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy

World J Gastroenterol. 2006 Jun 28;12(24):3915-8. doi: 10.3748/wjg.v12.i24.3915.

Abstract

Aim: To compare the one-day quadruple therapy with a standard 7-d triple therapy for H pylori eradication in a rural population of China.

Methods: A total of 396 patients with (13)C-urea breath test positive for H pylori were assigned into two groups: 239 patients received one-day quadruple therapy (amoxicillin 2000 mg qid; metronidazole 500 mg qid; bismuth citrate 900 mg qid and lansoprazole 60 mg once daily) and 157 patients received 7-d standard triple therapy (amoxicillin 1000 mg bid; clarithromycin 500 mg bid and lansoprazole 30 mg bid). All the patients underwent a (13)C-UBT to assess the eradication of H pylori infection six weeks after treatment.

Results: Two hundred and twenty-nine patients completed the one-day therapy (95.8%) and 148 patients completed the 7-d therapy (94.2%). The one-day therapy eradicated H pylori infection in 64 patients (27.95%). In contrast, 103 patients (69.59%) were H pylori negative after the 7-d therapy (P < 0.01).

Conclusion: This pilot study suggests there is no beneficial effect of the one-day therapy in treatment of H pylori infection compared with the 7-d standard therapy.

Publication types

  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Amoxicillin / administration & dosage
  • Amoxicillin / pharmacology
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Clarithromycin / administration & dosage
  • Clarithromycin / pharmacology
  • Clarithromycin / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / drug effects
  • Helicobacter pylori / pathogenicity*
  • Humans
  • Lansoprazole
  • Male
  • Metronidazole / administration & dosage
  • Metronidazole / pharmacology
  • Metronidazole / therapeutic use
  • Middle Aged
  • Omeprazole / administration & dosage
  • Omeprazole / analogs & derivatives
  • Omeprazole / pharmacology
  • Omeprazole / therapeutic use
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / pharmacology
  • Organometallic Compounds / therapeutic use
  • Pilot Projects
  • Prospective Studies
  • Rural Population*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Organometallic Compounds
  • Lansoprazole
  • Metronidazole
  • Amoxicillin
  • Clarithromycin
  • bismuth tripotassium dicitrate
  • Omeprazole